Tags

Type your tag names separated by a space and hit enter

Risks of novel therapeutics: gonococcemia in an immune-suppressed patient receiving eculizumab.
CMAJ. 2017 12 18; 189(50):E1558-E1560.CMAJ

Authors+Show Affiliations

PGY-4, Adult Hematology (Khandelwal), Department of Internal Medicine; Division of Infectious Diseases and the Eliot Phillipson Clinician-Scientist Training Program (Wright), Department of Medicine, University of Toronto; Division of Transfusion Medicine (Pavenski), Department of Laboratory Medicine; Division of Infectious Diseases (Taggart), Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ont.PGY-4, Adult Hematology (Khandelwal), Department of Internal Medicine; Division of Infectious Diseases and the Eliot Phillipson Clinician-Scientist Training Program (Wright), Department of Medicine, University of Toronto; Division of Transfusion Medicine (Pavenski), Department of Laboratory Medicine; Division of Infectious Diseases (Taggart), Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ont.PGY-4, Adult Hematology (Khandelwal), Department of Internal Medicine; Division of Infectious Diseases and the Eliot Phillipson Clinician-Scientist Training Program (Wright), Department of Medicine, University of Toronto; Division of Transfusion Medicine (Pavenski), Department of Laboratory Medicine; Division of Infectious Diseases (Taggart), Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ont.PGY-4, Adult Hematology (Khandelwal), Department of Internal Medicine; Division of Infectious Diseases and the Eliot Phillipson Clinician-Scientist Training Program (Wright), Department of Medicine, University of Toronto; Division of Transfusion Medicine (Pavenski), Department of Laboratory Medicine; Division of Infectious Diseases (Taggart), Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ont. taggartl@smh.ca.

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

29255100

Citation

Khandelwal, Aditi, et al. "Risks of Novel Therapeutics: Gonococcemia in an Immune-suppressed Patient Receiving Eculizumab." CMAJ : Canadian Medical Association Journal = Journal De l'Association Medicale Canadienne, vol. 189, no. 50, 2017, pp. E1558-E1560.
Khandelwal A, Wright JK, Pavenski K, et al. Risks of novel therapeutics: gonococcemia in an immune-suppressed patient receiving eculizumab. CMAJ. 2017;189(50):E1558-E1560.
Khandelwal, A., Wright, J. K., Pavenski, K., & Taggart, L. R. (2017). Risks of novel therapeutics: gonococcemia in an immune-suppressed patient receiving eculizumab. CMAJ : Canadian Medical Association Journal = Journal De l'Association Medicale Canadienne, 189(50), E1558-E1560. https://doi.org/10.1503/cmaj.170508
Khandelwal A, et al. Risks of Novel Therapeutics: Gonococcemia in an Immune-suppressed Patient Receiving Eculizumab. CMAJ. 2017 12 18;189(50):E1558-E1560. PubMed PMID: 29255100.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risks of novel therapeutics: gonococcemia in an immune-suppressed patient receiving eculizumab. AU - Khandelwal,Aditi, AU - Wright,Julie K, AU - Pavenski,Katerina, AU - Taggart,Linda R, PY - 2017/12/20/entrez PY - 2017/12/20/pubmed PY - 2018/12/12/medline SP - E1558 EP - E1560 JF - CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne JO - CMAJ VL - 189 IS - 50 SN - 1488-2329 UR - https://www.unboundmedicine.com/medline/citation/29255100/Risks_of_novel_therapeutics:_gonococcemia_in_an_immune-suppressed_patient_receiving_eculizumab L2 - http://www.cmaj.ca/cgi/pmidlookup?view=long&pmid=29255100 DB - PRIME DP - Unbound Medicine ER -